Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Plerixafor

Nature Reviews Drug Discovery volume 8, pages 105–107 (2009)Cite this article

Abstract

In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Plerixafor.

References

  1. Pusic, I. & DiPersio, J. F. The use of growth factors in hematopoietic stem cell transplantation. Curr. Pharm. Des. 14, 1950–1961 (2008).

    Article  CAS  PubMed  Google Scholar 

  2. Bensinger, W. et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol. 13, 2547–2555 (1995).

    Article  CAS  PubMed  Google Scholar 

  3. Lapidot, T. & Petit, I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol. 30, 973–981 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. De Clercq, E. The bicyclam AMD3100 story. Nature Rev. Drug Discov. 2, 581–587 (2003).

    Article  CAS  Google Scholar 

  5. Liles, W. C. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728–2730 (2003).

    Article  CAS  PubMed  Google Scholar 

  6. Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).

    Google Scholar 

  7. Broxmeyer, H. E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307–1318 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Burroughs, L. et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106, 4002–4008 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Devine, S. M. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1095–1102 (2004).

    Article  CAS  PubMed  Google Scholar 

  10. Flomenberg, N. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106, 1867–1874 (2005).

    Article  CAS  PubMed  Google Scholar 

  11. Pusic, I. et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol. Blood Marrow Transpl. 14, 1045–1056 (2008).

    Article  CAS  Google Scholar 

  12. DiPersio, J. et al. A Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 445 (2007).

    Google Scholar 

  13. DiPersio, J. F. et al. A Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 601 (2007).

    Google Scholar 

  14. Micallef, I. et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the Phase III (3101-NHL) study. ASH Annual Meeting Abs. 110, 602 (2007).

    Google Scholar 

  15. Calandra, G. et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transpl. 41, 331–338 (2008).

    Article  CAS  Google Scholar 

  16. IMS MIDAS (2007).

  17. Reams, A. Wachovia Equity Research Report. (Wachovia Capital Markets, 9 Dec 2008).

  18. Abrahams, B. Oppenheimer Equity Research Report. (Oppenheimer and Co., 3 Dec 2008).

Download references

Author information

Authors and Affiliations

  1. John F. DiPersio and Geoffrey L. Uy are at the Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA.,

    John F. DiPersio & Geoffrey L. Uy

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. jdipersi@im.wustl.edu; UYasothan@de.imshealth.com; p.kirkpatrick@nature.com,

    Peter Kirkpatrick

  4. UYasothan@de.imshealth.com,

    Peter Kirkpatrick

Authors
  1. John F. DiPersio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey L. Uy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J.F.D and G.L.U. have received honoraria and research support from Genzyme Corporation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DiPersio, J., Uy, G., Yasothan, U. et al. Plerixafor. Nat Rev Drug Discov 8, 105–107 (2009). https://doi.org/10.1038/nrd2819

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2819

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing